Rakuten Securities Inc. Invests $110,000 in Royalty Pharma plc (NASDAQ:RPRX)

Rakuten Securities Inc. acquired a new position in Royalty Pharma plc (NASDAQ:RPRX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,918 shares of the biopharmaceutical company’s stock, valued at approximately $110,000.

Other large investors also recently modified their holdings of the company. Allworth Financial LP grew its stake in shares of Royalty Pharma by 89.8% in the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 451 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 531 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of Royalty Pharma by 210.8% in the second quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 546 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Royalty Pharma in the first quarter valued at about $113,000. Finally, CWM LLC grew its stake in shares of Royalty Pharma by 75.9% in the third quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 2,064 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group lowered their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Bank of America lowered their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. JPMorgan Chase & Co. lowered their price objective on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, February 20th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Royalty Pharma currently has an average rating of “Buy” and an average target price of $46.75.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $27.61 on Thursday. Royalty Pharma plc has a fifty-two week low of $25.92 and a fifty-two week high of $36.67. The business has a 50 day moving average price of $29.81 and a two-hundred day moving average price of $28.50. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61. The firm has a market cap of $16.50 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 0.78 and a beta of 0.45.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.03 by $0.12. The company had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. Sell-side analysts expect that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be given a $0.21 dividend. The ex-dividend date is Thursday, May 16th. This represents a $0.84 annualized dividend and a dividend yield of 3.04%. Royalty Pharma’s payout ratio is 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.